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ABSTRACT
Previously, head and neck cancer (HNC) patients in Greenland have had significant diagnostic
delay and poor survival rates. From 2005-2009 several initiatives have been made to ensure faster
diagnosis and better survival. The aim of this study was to compare the prognosis before and
after these initiatives were introduced.
All Greenlandic patients diagnosed with HNC between 2005 and 2012 were included. Data
were retrieved from medical records and national databases and compared with the period 1994-
2003.
A total of 98 patients were identified. Diagnostic delay was significantly lower compared to
the period 1994–2004 (p=0.048). The 3-year overall survival was 56% for all HNC and 47% for
nasopharyngeal carcinomas. We found that patients with HNC between 1994 and 2003 had a
higher risk of death from all reasons compared with the period 2005–2012 (HR 2.17; CI 1.46–3.23)
after adjustments for stage and diagnostic delay.
Patients with head HNC in Greenland from 2005-2012 were diagnosed earlier and had a better
overall survival compared to the period 1994–2003. The change in survival is more likely to be
due to improvement in treatment rather than the initiated interventions. Although survival has
improved in Greenland, demographic problems and lack of specialists remain a challenge.
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Introduction
Head and neck cancer is frequent in the Inuit popula-
tion who primarily inhabit the circumpolar region with
the majority living in Greenland, Canada and Alaska [1].
Among the Inuit there is a high incidence of cancer of
the nasopharynx and salivary glands compared to their
respective national populations in Denmark, Canada
and the United States [2].
The majority of the nasopharyngeal carcinomas (NPC)
in the Inuit population is the undifferentiated type and
infection with Epstein–Barr virus is believed to be one of
the most important aetiological factors [3]. Furthermore,
studies have found an increased risk of NPC and salivary
gland cancer among first degree-relatives and in family
clusters supporting the existence of a hereditary compo-
nent [4].
Head and neck cancer is primarily a locoregional
disease and is therefore potentially curable with either
surgery or radiotherapy/chemo-radiotherapy or a com-
bination of both. It often metastasises regionally while
distant metastases are rare and typically seen in late
stage disease [5]. Early diagnosis of head and neck
cancer is important as it has been shown that diagnos-
tic delay increases risk of mortality [6]. Furthermore, it is
known that head and neck cancer proliferate rapidly
and that delay in treatment initiation can result in stage
progression [7,8] and have a negative effect on survival
[9]. This emphasises the importance of reducing diag-
nostic delay and treatment delay to ensure better prog-
nosis for patients with head and neck cancer.
Head and neck cancer arises in anatomically and
functionally complex areas. Impairment of these areas
from both treatment and disease can cause pain and
can damage essential functions as breathing, speech,
eating and sense of smell/taste which can have a pro-
found negative effect on physical, emotional and social
functioning [10]. Follow-up on head and neck cancer
patients is essential to identify locoregional recurrence
or metastasis and to assess treatment consequences
and restore nutritional and psychosocial status [11]
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Close and structured follow-up on these patients of
ear, nose and throat (ENT) specialists or oncologists is a
challenge in Greenland due to the demographic struc-
ture with scattered communities far from the regional
health centres and the difficulty in recruiting specia-
lists [12].
Jensen et al. investigated treatment response and
survival of head and neck cancer in the Greenland
Inuit population between 1994 and 2003 [13]. They
found significant delay in the diagnosis and treatment
of head and neck cancer. Furthermore, they found late
disease stage at diagnosis and corresponding poor sur-
vival rates irrespectively of disease site. Since that study
several initiatives have been made to ensure faster
diagnosis and better survival for patients with head
and neck cancer in Greenland. In early 2005 an ENT
specialist was based permanently in the capital Nuuk
in Greenland to refer, diagnose and perform follow-up
care for head and neck cancer patients. Previously this
was done by the primary sector or by ENT specialists
from Denmark visiting the remote areas once a year.
Additionally, a head and neck cancer awareness cam-
paign was aired on national television in autumn 2009.
At the same time healthcare professionals at Dronning
Ingrid’s Hospital, Nuuk and several other health care
districts in Greenland were educated in how to manage
head and neck cancer patients after treatment. In order
to investigate the impact of these initiatives, we per-
formed a new analysis of all head and neck cancer
patients in Greenland diagnosed 2005–2012 in order
to describe treatment delay, diagnostic delay and prog-
nosis compared with the period 1994–2003.
Materials and methods
This is a retrospective study including all patients resi-
dent in Greenland diagnosed with head and neck can-
cer between 1 June 2005 and 31 December 2012, and
these data was compared with data for the time period
1 January 1994 to 31 December 2003.
Data for the earlier period has been described pre-
viously [13], so we give a summary here. The Danish
civil registration system, the Danish Cancer registry and
hospital-based registries were used to identity all
patients resident in Greenland diagnosed with head
and neck cancer. A total of 125 inuit patients were
identified. Date of first symptom, confirmed histological
diagnosis and first day of treatment were obtained from
medical records. Information on death was obtained
from patient files and the medical public health officer
in Greenland. All surviving patients were observed for
at least 4 years.
Data for the latest period as well as comparison of
the two periods will be described in the following sec-
tion. All individuals in Greenland are registered in the
Danish Civil Registration system [14] and have a civil
registration number (CRS). Patients with a Greenlandic
CRS number combined with an ICD-10 code for carci-
noma in the pharynx, larynx, oral cavity, nasal cavity
and sinuses, salivary gland and thyroid gland were
included. Patients with cervical lymph node metastases
but an unknown primary tumour were included
because over 90% of these represent malignancies
within Waldeyer’s ring in the pharynx [15]. The diag-
noses were validated using the Danish Pathology
Registry. Clinical information was obtained from medi-
cal records from Rigshospitalet in Copenhagen,
Denmark, and from Dronning Ingrid’s Hospital in
Nuuk, Greenland. Tumours were staged prospectively
according to the Union for International Cancer Control
(UICC) version 7.
Time course
Dates for the following events were registered: first
symptom, confirmed histological diagnosis, first day of
treatment and death. Age was estimated at the time of
histological diagnosis. Diagnostic delay was calculated
from date of first symptom to date of histological diag-
nosis. The time from verified histological diagnosis to
first day of treatment was calculated as treatment delay
and finally the overall delay was calculated from date of
first symptom to first day of treatment. Information on
death was extracted from the journals last updated 18
October 2015.
Statistical analysis
Incidence rates were age-standardised according to the
2000 world standard population.
The Mann–Whitney U test was used to assess differ-
ences between groups of continuous variables. The
relationship between two categorical variables was cal-
culated using chi-square test.
We estimated overall survival rates using the Kaplan–
Meier model. Overall survival was defined as the time
from the initial diagnosis to date of death. Patients were
followed until death or the follow-up cut-off date 18
October 2015. Censoring was made if patients were
alive at the follow-up cut-off date. Univariate compar-
ison of survival was performed using the log-rank test.
The variables age, gender, localisation, stage, diagnostic
delay and period were entered into a multivariate ana-
lysis using a Cox proportional hazards model with back-
ward elimination. All results are given as two-sided
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values. All statistical analyses were performed using IBM
SPSS statistics version 22.0.0.
Results
The 98 patients diagnosed with head and neck cancer in
Greenland between 2005 and 2012 comprised 39 females
and 59menwith an age range of 5–81 years and amedian
age of 57 years (one patient aged 5 years had an embry-
onal rhabdomyosarcoma). The age-standardised inci-
dence rate for all head and neck cancers was 25/100,000
persons-years for males and 19/100,000 persons-years for
females. The incidence rate of NPC was 9/100,000 per-
sons-years for males and 4/100,000 persons-years for
females. The incidence of laryngeal carcinomas was low
with rates of 2/100,000 persons-years for males and <1/
100,000 persons-years for females (Table 1). The most
common tumour localisation was the nasopharynx with
almost one-third of all cases.
According to UICC TNM classification, we found that
14 (14%) were stage I–II, 62 (63%) were stage III–IV and
22 (22%) were of unknown stage (Table 2). For the
largest group, NPC, the majority of patients (87%)
were diagnosed in stage III–IV.
The median delay from first symptom to histological
diagnosis (diagnostic delay) for all patients was 168 days
with a significant difference (p=0.02) between the two
genders with females having a larger median diagnostic
delay than men (218 days vs. 139 days).
Three patients did not receive any treatment, one
refused treatment, one could not receive treatment due
to severe morbidity and no data was available on why
the last patient did not receive treatment.
In Table 3 the collected data from the period
2005–2012 has been compared with the prior study
period (1994–2003) using univariate statistics. In the
comparison, stage was divided into two groups, stage
I–II and stage III–IV. We found no significant differences
between the two populations regarding the distribu-
tion in incidence, age, gender, localisation or stage. We
found that diagnostic delay was significantly lower in
the latest period compared to the period 1994–2004
(p=0.048). For all head and neck cancer patients we
found a 3-year overall survival of 56% compared with
39% in the prior period (Figure 1). The 3-year overall
survival for NPC was 47% and for oral and oropharyn-
geal carcinomas it was 46% and 43%, respectively.
When we compared overall survival for all head and
neck cancers using the log-rank test we found a sig-
nificant difference between the two population groups
(p=0.04). The greatest difference in overall survival was
found for NPC (p=0.026) but also oral -and oropharyn-
geal carcinomas had a better overall survival in this
study period compared to 1994–2003 although this
difference was not significant.
To examine whether the significant improvement
in overall survival in the present study compared to
the latter could be explained by differences in the
variables collected, we performed a multivariate ana-
lysis. We found that patients with head and neck
cancer from Greenland between 1994 and 2003 had
a significant increased risk of death from all reasons
with a hazard ratio of 2,17 (CI 1.46–3.23) compared
with the period 2005–2012 after adjusting for age,
gender, localisation, stage and diagnostic delay
(Table 4).
Table 1. Numbers and incidence of head and neck cancer per 100,000 persons-years in Greenland in the period 2005–2012.
Males (n) Age mean Crude rate Asa rate Females (n) Age mean Crude rate Asa rate
Nasopharynx 22 59 10 9 8 56 4 4
Oropharynx 10 60 5 4 4 59 2 2
Hypopharynx 6 62 3 3 0
Larynx 6 58 3 2 1 52 < 1 < 1
Salivary gland 5 39 2 2 5 53 3 2
Oral cavity 6 62 3 3 7 63 4 3
Thyroid 1 50 < 1 < 1 12 47 6 6
Others 3 68 1 1 2 36 1 1
All cancers 59 58 26 25 39 53 20 19
aAge-standardised using the 2000 world standard population.
Table 2. Stage according to UICC 1997 in Greenlandic head and neck cancer patients.
2005–2012 1994–2003
n Stage I–II % Stage III–IV % Stage unknown % n Stage I–II % Stage III–IV % Stage unknown %
Oral cavity 14 36 36 29 25 20 68 12
Nasopharynx 30 7 87 7 42 10 88 2
Oropharynx 14 0 81 19 13 23 69 8
Salivary gland 10 30 60 10 13 54 39 8
All head and neck cancers 98 14 63 22 125 24 69 7
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Discussion
In this study, we have retrospectively investigated all
head and neck cancer patients in the largest Inuit popu-
lation in the world over a period of 7.5 years and com-
pared the time course and prognosis of these patients
with the period 1994–2003. In multivariate analysis, we
found a significant better overall survival for all head and
neck cancer patients in Greenland compared with the
period 1994–2003. The most significant improvement in
overall survival was seen for NPC patients where the
3-year overall survival increased from 23% to 47%.
Furthermore, we found a significant shorter diagnostic
delay in this study compared to the period 1994–2003.
The disease stage at diagnosis seems to be largely
unchanged for NPC between the two periods with
Table 3. Comparison of all head and neck cancer patients in Greenland between the period 1994–2003 and 2005–2012.
Variables 1994–2003 2005–2012 p-Value
Asa rate females (cases per 100,000 persons-years) 19 20
Asa rate males (cases per 100,000 persons-years) 28 26
Age (median) 58 57.5 0.923
Gender (n (%)) 0.975
Female 50 (40%) 39 (40%)
Male 75 (60%) 59 (60%)
Time course (median days)
Diagnostic delay 207 168 0.048
Treatment delay 40 32 0.272
Overall delay 249 201 0.051
Localisation (n (%)) 0.539
Nasopharynx 42 (34%) 30 (31%)
Oropharynx 13 (10%) 14 (14%)
Hypopharynx 6 (5%) 6 (6%)
Larynx 10 (8%) 7 (7%)
Salivary gland 13 (10%) 10 (10%)
Oral cavity 27 (22%) 13 (13%)
Thyroid 12 (10%) 13 (13%)
Other 2 (2%) (a) 5 (5%) (b)
Stage (n (%)) 0.114
Stage I–II 33 (26%) 14 (14%)
Stage III–IV 83 (66%) 62 (63%)
Unknown stage 9 (7%) 22 (22%)
Overall survival (3-years OS) 39% 56% 0.04
Total (n) 125 98
a Age-standardised using the 2000 world standard population.
b Unknown primary.
c Three sinonasal, one embryonal rhabdomyosarcoma and one unknown primary.
Figure 1. Overall survival in Greenland for all head and neck cancer patients.
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the greatest part of NPC patients diagnosed in the more
advanced stages. However, even at the same stage there
may be large variations in tumour size. As for the other
tumour localisations, it is not possible to describe trends in
stage between the periods due to the lower number of
patients and a larger proportion of cases with unknown
stage.
Patients with NPC in the United States and
Denmark have also achieved improvement in survival
over the last decades. Jia-Wei et al. analysed data from
the Surveillance Epidemiology and End Results pro-
gramme and found an increase in 5-year overall survi-
val from 46.6 % between 1990 and 1999 to 54.7%
between 2000 and 2007 [16]. The same development
was seen in Denmark where the 3-year overall survival
for NPC was 72% in a Danish study from 2008 [17]
which is significantly better than previous studies [18].
One of the main reasons for the increase in survival
rates for NPC patients was the introduction of conco-
mitant chemo-radiotherapy and the use of intensity-
modulated radiotherapy. In 1998 Al-Sarraf et al. found
improvement in survival for patients with advanced
NPC receiving chemo-radiotherapy compared to radio-
therapy alone [19] and later this was verified in a
Cochrane review [20]. Although the overall survival in
Greenland has improved significantly, it is still not
comparable to Denmark or the United States. Other
factors that could explain the improvement in survival
are the small reduction in the use of tobacco and
alcohol over the past two decades [21,22] as well as
the more organised follow-up procedures, use of CT
and MRI scanning and more focus on rehabilitation
including nutrition which was enrolled after an ENT
specialist was permanently based in Nuuk, Greenland,
from June 2005.
Comorbidity is common among head and neck can-
cer patients and is known to have a significant negative
impact on outcome [23]. Advances in management of
comorbidity or decreasing comorbidity burden over
time might also have a positive influence on overall
survival.
Until now human papilloma virus does not seem to
play a dominant role in the development of oropharyn-
geal cancers in Greenland and cannot serve as
explanation of the better survival in Greenland [24].
Furthermore, patients with head and neck cancer have
probably been referred faster than before when the
patients were diagnosed by non-specialists or ENT-spe-
cialists visiting once a year. This could explain the signifi-
cant shorter diagnostic delay. Unfortunately, this change
was not enough to diagnose patients in an earlier stage
nor to have effect on survival (HR = 1 for diagnostic delay
in Table 4).
Another explanation for the significant improvement
in diagnostic delay could be the increased focus on
head and neck cancer in Greenland with awareness
campaigns on national television, which could have
lead patients to the doctor earlier than before.
Our study naturally has some limitations. Firstly,
diagnostic delay is subject to recall bias since it is
based on retrospective, self-reported data on the
time of first symptoms. However, recall bias would
probably affect both periods equally, so the reduction
in diagnostic delay between the two periods is prob-
ably not strongly affected by recall bias. Secondly, for
the comparison of 3-year survival we haven’t adjusted
for treatment, despite this being probably the most
important factor. Therefore, it is difficult to estimate
the effect of intervention. Thirdly, as the Greenland
population is small, there is a risk of coincidental
changes in treatment delay, diagnostic delay and
prognosis.
In summary, we found that patients with head and
neck cancer in Greenland between 2005 and 2012 were
diagnosed earlier and had a better overall survival com-
pared to the period 1994–2003. Although survival has
improved in Greenland, demographic problems and
lack of specialists remain a challenge. The interval
between first symptom and diagnosis is still very long,
and the majority of patients are diagnosed in late stages.
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Table 4. Multivariate analysis with hazard ratios for death among all head and neck cancer patients in Greenland from the periods
1994–2003 and 2005–2012.
Covariate HR p-Value 95% CI
Age 1.06 <0.001 1.05–1.08
Gender 0.85 0.41 0.58–1.25
Localisation 0.95 0.22 0.87–1.03
Stage 1.87 <0.001 1.49–2.35
Diagnostic delay 1 0.89 0.99–1.00
Period 2.18 <0.001 1.46–3.23
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